26 Jul 2018 09:01
Horizon Discovery Group plc
Block Listing Six Monthly Return and Block Listing Application
26 July 2018
Horizon Discovery Group plc (LSE: HZD) ("Horizon") provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
Name of applicant: | Horizon Discovery Group plc | |
Name of scheme(s): | a) Horizon Discovery Limited Enterprise Management Incentive Share Option Scheme b) Horizon Discovery Group plc Long Term Incentive Plan c) Horizon Discovery 2014 Sharesave Scheme d) Horizon Discovery Group plc US Employee Stock Purchase Plan | |
Period of return (from / to): | From: 27 January 2018 | To: 26 July 2018 |
Number of securities originally admitted and date of admission | Total of 3,000,000 ordinary shares of 1p each, split: a) 1,398,000 b) 1,392,000 c) 110,000 d) 100,000 Admission date 26 July 2017 | |
Balance of unallotted securities under schemes from previous return: | Total of 2,574,510 ordinary shares of 1p each, split a) 1,177,344 b) 1,306,640 c) 24,671 d) 65,855
| |
Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for): | Total of 500,000 ordinary shares of 1p each, split a) 0 b) 150,000 c) 150,000 d) 200,000 As applied for in the below paragraph. | |
Less: Number of securities issued/allotted under scheme(s) during period: | Total of 498,653 ordinary shares of 1p each, split a) 398,808 b) 82,951 c) 16,894 d) 0 | |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | Total of 2,575,857 ordinary shares of 1p each, split a) 778,536 b) 1,373,689 c) 157,777 d) 265,855
| |
BLOCK LISTING APPLICATION
Horizon announces that an application has today been made to the London Stock Exchange for the admission of 500,000 Ordinary Shares of 1 pence each (the "Ordinary Shares") in the Company under the Company's existing block listing scheme. These Ordinary Shares will be available to satisfy future exercises of options in accordance with the following employee share plans:
· Horizon Discovery Group plc Long Term Incentive Plan (up to 150,000 shares)
· Horizon Discovery 2014 Sharesave Scheme (up to 150,000 shares)
· Horizon Discovery Group plc US Employee Stock Purchase Plan (up to 200,000 shares)
It is expected that Admission will occur on 27 July 2018. When issued, these Ordinary Shares will rank pari passu with the existing Ordinary Shares.
ENDS
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Ian Gilham, Executive Chairman
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".